Breast Cancer Clinical Trial
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
Documented incurable cancer with one of the following histologies: nonsmall cell lung cancer, renal cell cancer, triple negative breast cancer, colorectal cancer with microsatellite instability(MSI), bladder cancer, cervical cancer, uterine cancer, sarcoma, endometrial cancer, and metastatic castration resistant prostate cancer.
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
For Escalation: At least 1 but not more than 5 prior systemic therapies for advanced/ recurrent or progressing disease. For Expansion: Subject must have progressed on, be refractory to, or intolerant to 1-3 prior systemic therapies.
Willingness to provide tumor biopsies.
History of severe hypersensitivity reaction to monoclonal antibodies.
Subjects who have received prior therapy with regimens containing cytotoxicT-lymphocyte antigen-4 (CTLA-4), programmed cell death ligand 1 (PDL1), or PD1 antagonists are NOT permitted to enroll unless all adverse events (AEs) while receiving prior immunotherapy have resolved to Grade 1 or baseline prior to screening.
History of (non-infectious) pneumonitis that required steroids or subject has current pneumonitis.
The use of any investigational medication or device in the 30 days prior to screening and throughout the study is prohibited.
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 26 Locations for this study
Tucson Arizona, 85711, United States
Duarte California, 91010, United States
San Francisco California, 94143, United States
New Haven Connecticut, 06519, United States
Miami Florida, 33136, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60637, United States
Baltimore Maryland, 21224, United States
Boston Massachusetts, 02215, United States
Las Vegas Nevada, 89169, United States
Albany New York, 12206, United States
Buffalo New York, 14263, United States
New York New York, 10029, United States
Huntsville North Carolina, 28078, United States
Cincinnati Ohio, 45242, United States
Oklahoma City Oklahoma, 73104, United States
Pittsburgh Pennsylvania, 15232, United States
Greenville South Carolina, 29605, United States
Nashville Tennessee, 37203, United States
Dallas Texas, 75230, United States
Fairfax Virginia, 22031, United States
Milwaukee Wisconsin, 53226, United States
Camperdown New South Wales, 2050, Australia
Darlinghurst New South Wales, 2010, Australia
Westmead New South Wales, 3168, Australia
Herston Queensland, 4029, Australia
Clayton Victoria, 3168, Australia
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.